Technological advances in the field of radiation oncology over the last decade have revolutionized care for cancer patients in the US and worldwide. These technological advancements have been both hardwareand software-based. More importantly, however, a major shift in the clinical paradigm exemplifies this ground-breaking change. Innovative approaches incorporating both technological and clinical changes have resulted in a complex and elegant mix of imaged-based approaches using computed tomography (CT), magnetic resonance, and positron emission tomography (PET). These are used in conjunction with treatment delivery techniques including intensity-modulated radiation therapy (IMRT), image-guided brachytherapy, and adaptive treatment approaches-image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). Central to the success of any local therapy is the accurate diagnosis of tumor extent.
Principles of Positron Emission Tomography
PET uses a short-lived radiotracer that upon decay emits a positron-the antimatter counterpart of an electron. The positron is a highly unstable particle that almost instantaneously encounters an electron in a process called annihilation. This results in two gamma photons of 511 keV being emitted perpendicular to each other. This decay can be recognized by a ring of detectors that are able to localize the origin of each positron, thus creating a map of activity proportional to metabolic differences. Since there is an altered metabolic characteristic of tumor cells compared with surrounding normal tissues, an 'activity map' can be created reflecting the differing regions within the body. The uncontrolled cellular proliferation, which is the hallmark of malignant transformation, offers the perfect target for the diagnosis and evaluation of a variety of cancers. 2-[18F]-fluoro-2-deoxy-D glucose (FDG), a glucose analog, is the most commonly used radiotracer. This tracer, administered intravenously, is transported from the extra-cellular compartment to the intra-cellular compartment by the membrane-bound glucose transporter. Once intra-cellular, FDG is phosphorylated by hexokinase to form FDG-6-PO4 in proportion to the glycolytic rate of the cell (see Figure 1) . Unlike glucose-6-PO4, the normal metabolite of hexokinase, FDG-6-PO4 cannot enter the glycolytic pathways and therefore accumulates intra-cellularly. As a result, this differential accumulation can be quantified and used to form an image of tumor 
Why PET-CT Simulation?
Beginning in the early 1980s and escalating in subsequent years, functional imaging and specifically PET has gained increasing importance in the diagnosis and staging of a variety of malignancies, including lymphomas, head and neck cancers, lung and esophageal cancers, melanomas, brain tumors, and gastrointestinal cancers. Using FDG as the primary tracer, numerous studies have demonstrated the superiority of PET over CT in a variety of disease states.
Although useful in diagnosis and staging, stand-alone PET images have a less than optimal role in radiation treatment planning, predominantly because of their lack of anatomical information. Modern radiation therapy treatment planning is currently based on computed tomography with three-dimensional reconstructions, known as 3-D conformal radiation therapy (3D-CRT).
Complementary imaging modality such as magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT), among others, can be fused with the simulation CT to aid in target or normal tissue definition. Given its lack of the customary anatomical detail necessary for conformal radiation therapy, stand-alone PET has been difficult to use for planning purposes. Furthermore, the lack of a simple methodology to fuse the PET dataset with the simulation CTs dataset has limited the role of these systems in radiation oncology. His clinical and research interests include the integration of advanced imaging in oncology, such as positron emission tomography/computed tomography (CT) and 4-D CT, which are used in modern radiation treatment planning, and their delivery as cranial and body radiosurgery. He is the author and co-author of numerous journal articles, book chapters, monographs, and abstracts and continues to teach and mentor medical students and resident in the tradition of the biopsychosocial model.
simulation dataset. By definition, the CT from the PET-CT study is the CT simulation. An image of this set-up is depicted in Figure 2 .
Outcome Studies Using PET and PET-CT in Oncology
The use of PET-CT for radiation treatment planning is a relatively recent 
Head and Neck Cancers
Nowhere is the need for highly conformal techniques more obvious than in the treatment of head and neck cancers. Multiple sensitive structures including the major and minor salivary glands, mandible, spinal cord, and brainstem have made IMRT the modality of choice in treating these cancers. Figure 3 .
Thoracic Tumors
For lung cancers, the presence of mediastinal involvement dramatically alters the outcome of these patients treated with unimodality or multimodality therapy. It is clear that PET and PET-CT has an excellent negative predicative value (87-100%) compared with surgical staging. The positive predictive value, however, remains less than optimal at <80%.
Therefore, in patients with PET-negative studies of the mediastinum, mediastinal and/or elective nodal irradiation can be safely omitted. Others have shown that PET-CT is more accurate in predicting nodal stage than PET or CT alone in non-small cell lung cancer. 3 Elimination of elective nodal stations by effective prediction of involvement has enabled dose escalation programs such as reported by Ruysscher et al. 4 They were able to escalate therapeutic doses to 84 Gy before reaching dose-limiting toxicities necessitating study closure. More importantly, the treatment of lung cancer is often complicated by an associated infiltrate and/or atelectasis. In this setting, it is often quite difficult to distinguish these processes from the to 22%, although in 10% of patients the PTV actually grew as a result of functional imaging. 5 Others have shown similar improvement in tumor volume definitions using PET-CT for non-small-cell lung cancer (NSCLC). 6 For small-cell lung cancer, the use of PET-CT is less established. However, it appears that PET-CT will move a substantial proportion of patients to the next stage, thereby potentially altering their management.
In terms of predicting long-term survival, there is clear evidence that the change in FDG PET uptake can predict survival, leading to the conclusion that morphometric tumor response after treatment may strongly correlate with metabolic remission by PET. 
Gynecological Cancers
PET and PET-CT have been shown to be superior to CT alone in the staging of cervical cancer. 8, 9 The detection of occult pelvic and para-aortic metastases using PET-CT has been used to select patients who might benefit from extended-field intensity-modulated radiation therapy (EF-IMRT). 10 Furthermore, at least one author has proposed dose escalation using EF-IMRT in locally advanced cervical cancer. 11 Although only a dosimetric study,using 2.4 Gy per fraction as an integrated boost to known para-aortic disease, the author's own institutional experience appears to indicate that such an approach is both clinically feasible and effective in sterilizing known disease without undue treatment-related toxicities. Chung et al. have
shown that post-treatment FDG-PET surveillance in 121 patients was effective in detecting recurrence in 76 patients, 20 of whom were asymptomatic. 12 Other research groups have shown similar results. 
Brain Tumors
Contrast-enhanced CT and MRI remain the basis for the current practice of radiation treatment planning for brain tumors. Solberg and colleagues have 
Surveillance and Detection of Recurrence
The detection of recurrent disease is clearly a great opportunity for PET-CT.
It is proposed that early detection of residual or recurrent disease may offer the opportunity for early salvage, which may alter the course of a variety of malignancies.
System Costs
In the author's practice, PET-CT simulations are read as diagnostic studies while being simultaneously used for radiation treatment planning. This offers the best of both worlds and eliminates the need for a separate imaging study.
Cost per systems is approximately US$2.2 million, which includes the PET-CT, the carbon fiber flat table-top necessary for radiation treatment simulation, and in-room movable lasers, among other radiation-specific devices.
A Novel Implementation of PET-CT Simulation
Traditionally, high-end technologies, including imaging systems, have been relegated to tertiary-care hospitals and specialty facilities, thereby limiting accessibility of state-of-the-art care to the vast majority of cancer 
Imaging as unique as each patient

